Scipher Medicine Strengthens Leadership Team with Appointment of Sam A Davis, JD as General Counsel

SEPTEMBER 24, WALTHAM, MA – Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announces the appointment of Sam A. Davis, JD, as General Counsel. Sam will lead all legal matters, including strategic partnerships, future collaborations, and growth financing transactions, as the company enters its next stage of growth as a leading diagnostics and therapeutics company

“We are excited to welcome Sam to the Scipher management team,” said Alif Saleh, Chief Executive Officer of Scipher Medicine.  “Sam’s life sciences experience, innovative vision, and collaborative mindset will be critical as the company expands its current franchise and pipeline of upcoming drugs across US and into global markets..”

“Scipher is developing exciting and innovative novel solutions to some of the greatest challenges in healthcare today, using cutting edge technology,” said Sam. “It’s a privilege to be part of a team empowering providers and payers to reduce excessive waste and improve patient outcomes.”

Sam brings robust experience as a leading life sciences attorney in various leadership positions with EQRx, Inc. Goodwin Procter LLP and Mcdermott, Will & Emery LLP.  Prior to joining Scipher, Sam was Associate General Counsel, Vice President Legal Affairs at EQRx, Inc, where he led all legal matters, including private and public financings, multiple global license and collaborations, and payer partnerships.

Scipher Medicine’s robust test pipeline is targeting approved therapies with low patient response rates for multiple complex autoimmune diseases, allowing clinicians to make evidence-based therapy decisions and improve treatment outcomes while saving payers unnecessary spend on ineffective drugs, addressing a $42 billion market opportunity.

About PrismRA®

PrismRA, a liquid signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual’s molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the world’s largest selling drug class, so non-responders can be prescribed alternative effective therapy and avoid unnecessary dose escalations or drug cycles. Providers now have objective data to guide therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit www.PrismRA.com.

About Scipher Medicine®

Scipher Medicine, a precision immunology company, holds the fundamental belief that patients deserve simple answers to treatment options based on scientifically backed data. Leveraging our proprietary Network Medicine platform and artificial intelligence, we commercialize liquid- based tests revealing a persons’ unique molecular disease signature and match such signature to the most effective therapy, ensuring optimal treatment from day one. The unprecedented quantity of patient molecular data generated from our tests further drives the discovery and development of novel and more effective therapeutics. We partner with payers, providers, and pharma along the healthcare value chain to bring precision medicine to autoimmune diseases. Visit www.sciphermedicine.com and follow Scipher on Twitter, Facebook, and LinkedIn.

Media Contact:
Alexander Petti
Alexander@TakeOnCommunications.com
201.978.4882

Scipher Medicine Company Contact: 
Andrea M. Moore
Andrea.Moore@Scipher.com
801.209.1175